financetom
Business
financetom
/
Business
/
Cognex Q2 revenue beats estimates, adjusted EPS rises 12%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cognex Q2 revenue beats estimates, adjusted EPS rises 12%
Jul 30, 2025 2:13 PM

Overview

* Cognex ( CGNX ) Q2 revenue grows 4% yr/yr, beating analyst expectations

* Adjusted EPS rises 12% to $0.25, surpassing estimates

* Operating expenses decline 3% due to disciplined cost management

Outlook

* Cognex ( CGNX ) expects Q3 revenue between $245 mln and $265 mln

* Company sees Q3 adjusted EPS between $0.24 and $0.29

* Cognex ( CGNX ) anticipates Q3 adjusted EBITDA margin of 19.5% to 22.5%

Result Drivers

* LOGISTICS AND AUTOMATION - Revenue growth driven by strength in Logistics and Factory Automation, particularly Consumer Electronics and Packaging

* COST MANAGEMENT - Operating expenses declined 3% due to disciplined cost management, contributing to margin improvements

* ONEVISION PLATFORM - Launch of OneVision cloud platform for AI-powered Machine Vision marks strategic initiative

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $249 mln $246.10

Revenue mln (15

Analysts

)

Q2 Beat $0.25 $0.24

Adjusted (15

EPS Analysts

)

Q2 $43 mln

Operatin

g income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

* Wall Street's median 12-month price target for Cognex Corp ( CGNX ) is $37.00, about 7.4% above its July 29 closing price of $34.26

* The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Update: Dave Shares Decline After Amendment to Coastal Community Bank Agreement
Update: Dave Shares Decline After Amendment to Coastal Community Bank Agreement
Aug 6, 2025
12:08 PM EDT, 08/06/2025 (MT Newswires) -- (Updates with stock price movement in the headline and the first paragraph.) Dave ( DAVE ) shares were down by more than 22% in recent Wednesday trading after the company amended a program agreement with Coastal Community Bank, a unit of Coastal Financial (CCB), to move a significant portion of its ExtraCash receivables...
Update: Market Chatter: Bank of America Analysts to Face Reassignment if They Accept Jobs Elsewhere
Update: Market Chatter: Bank of America Analysts to Face Reassignment if They Accept Jobs Elsewhere
Aug 6, 2025
12:09 PM EDT, 08/06/2025 (MT Newswires) -- (Updates with company response in fourth paragraph.) Bank of America ( BAC ) is asking its junior bankers to disclose if they have accepted job opportunities elsewhere and telling them they face reassignment to other areas if they do so, Bloomberg News reported Wednesday, citing a source familiar with the matter. Bankers who...
Astria Therapeutics Strikes Licensing Deal in Japan
Astria Therapeutics Strikes Licensing Deal in Japan
Aug 6, 2025
12:06 PM EDT, 08/06/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Wednesday it has licensed the development and commercialization rights for its hereditary angioedema drug candidate, navenibart, in Japan to Kaken Pharmaceutical. The company said it will receive an upfront payment of $16 million, with the potential for an additional $16 million in milestone payments. Astria said it...
Copyright 2023-2026 - www.financetom.com All Rights Reserved